Addex Therapeutics Ltd (ADXN)

NASDAQ · Health care · Pharmaceutical Preparations · Financial statements, TTM figures and earnings dates

In fiscal year 2024 (ended December 31, 2024), Addex Therapeutics Ltd reported revenue of CHF 404.1K and net income of CHF 7.1M. Annual financial statements are available for fiscal years 2017 to 2024, taken from the company's filings with the SEC.

Open interactive financials →

Key financials

CHF	FY2024 2024-12-31	FY2023 2023-12-31	FY2022 2022-12-31	FY2021 2021-12-31	FY2020 2020-12-31
Income statement
Revenue	CHF 404.1K	CHF 1.6M	CHF 1.4M	CHF 2.9M	CHF 3.6M
Operating income	−CHF 2.8M	−CHF 2.2M	−CHF 10.5M	−CHF 15.5M	−CHF 12.2M
Net income	CHF 7.1M	−CHF 10.6M	−CHF 20.8M	−CHF 15.4M	−CHF 12.9M
Diluted EPS	CHF 0.07	−CHF 0.14	−CHF 0.46	−CHF 0.45	−CHF 0.48
Cash flow
Operating cash flow	−CHF 5.4M	−CHF 8.0M	−CHF 16.4M	−CHF 14.7M	−CHF 12.2M
Capital expenditure	CHF 1.3K	CHF 6.8K	CHF 581	CHF 31.5K	CHF 59.4K
Free cash flow	−CHF 5.4M	−CHF 8.0M	−CHF 16.4M	−CHF 14.7M	−CHF 12.2M
Balance sheet
Cash and equivalents	CHF 3.3M	CHF 3.9M	CHF 7.0M	CHF 20.5M	CHF 18.7M
Total assets	CHF 10.7M	CHF 4.6M	CHF 8.3M	CHF 22.5M	CHF 20.2M
Total liabilities	CHF 1.0M	CHF 3.5M	CHF 3.4M	CHF 5.6M	CHF 5.6M
Total debt	CHF 0	CHF 0	CHF 0	CHF 0	CHF 0
Shareholders' equity	CHF 9.7M	CHF 1.1M	CHF 4.9M	CHF 16.9M	CHF 14.6M

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in CHF as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full ADXN page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open ADXN financials →